

January 31, 2025

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 543322

Ref: Scrip Name: ALIVUS

Dear Sirs,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is to inform you that the United States Food & Drug Administration (USFDA) today completed a routine GMP inspection at our API manufacturing facility located at Plot No. 3102 to 3109, 3103, GIDC Industrial Estate, Ankleshwar, Gujarat. The inspection was conducted from 27th January, 2025 to 31st January, 2025. We have been issued a Form 483 with one observation, which we will address within the stipulated timeline.

This is for your information and record.

Thanking you.

Your Sincerely,
For Alivus Life Sciences Limited
(formerly known as Glenmark Life Sciences Limited)

Rudalf Corriea
Company Secretary & Compliance officer

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited)

Corporate Office:

4th Floor, OIA House, 470, Cardinal Gracious Road
Andheri (E), Mumbai 400 099, Maharashtra, India

Registered Office:

Plot No 170-172, Chandramouli Industrial Estate
Mohol Bazarpet, Solapur 413 213, India

T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: complianceofficer@glenmarklifesciences.com | W: www.alivus.com

